Back to Search Start Over

Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.

Authors :
Jean-Pierre, Vincent
Sorlin, Pauline
Pantel, Alix
Chiron, Raphaël
Lavigne, Jean-Philippe
Jeannot, Katy
Marchandin, Hélène
Amara, Marlène
Cadot, Lucile
Dauwalder, Olivier
Degand, Nicolas
Demar, Magalie
Dupin, Clarisse
Fangous, Marie-Sarah
Franczak, Claire
Garnier, Fabien
Guiet, Pascal
Guinard, Jérôme
Hombrouck-Alet, Cécile
Kaoula, Atika
Source :
Annals of Clinical Microbiology & Antimicrobials; 6/17/2024, Vol. 23 Issue 1, p1-13, 13p
Publication Year :
2024

Abstract

Background: Achromobacter spp. are opportunistic pathogens, mostly infecting immunocompromised patients and patients with cystic fibrosis (CF) and considered as difficult-to-treat pathogens due to both intrinsic resistance and the possibility of acquired antimicrobial resistance. Species identification remains challenging leading to imprecise descriptions of resistance in each taxon. Cefiderocol is a broad-spectrum siderophore cephalosporin increasingly used in the management of Achromobacter infections for which susceptibility data remain scarce. We aimed to describe the susceptibility to cefiderocol of a collection of Achromobacter strains encompassing different species and isolation sources from CF or non-CF (NCF) patients. Methods: We studied 230 Achromobacter strains (67 from CF, 163 from NCF patients) identified by nrdA gene-based analysis, with available susceptibility data for piperacillin–tazobactam, meropenem and trimethoprim–sulfamethoxazole. Minimal inhibitory concentrations (MICs) of cefiderocol were determined using the broth microdilution reference method according to EUCAST guidelines. Results: Strains belonged to 15 species. A. xylosoxidans represented the main species (71.3%). MICs ranged from ≤ 0.015 to 16 mg/L with MIC<subscript>50/90</subscript> of ≤ 0.015/0.5 mg/L overall and 0.125/2 mg/L against 27 (11.7%) meropenem-non-susceptible strains. Cefiderocol MICs were not related to CF/NCF origin or species although A. xylosoxidans MICs were statistically lower than those of other species considered as a whole. Considering the EUCAST non-species related breakpoint (2 mg/L), 228 strains (99.1%) were susceptible to cefiderocol. The two cefiderocol-resistant strains (A. xylosoxidans from CF patients) represented 3.7% of meropenem-non-susceptible strains and 12.5% of MDR strains. Conclusions: Cefiderocol exhibited excellent in vitro activity against a large collection of accurately identified Achromobacter strains, irrespective of species and origin. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14760711
Volume :
23
Issue :
1
Database :
Complementary Index
Journal :
Annals of Clinical Microbiology & Antimicrobials
Publication Type :
Academic Journal
Accession number :
177949099
Full Text :
https://doi.org/10.1186/s12941-024-00709-z